The way to make money in pharma with bioprinting?…Develop the drugs

From the article: 3D complex biology platforms have tremendous value to offer. The way this value is offered is extremely important. It will take much longer to go head-to-head with animal models to create disruption given how extensive it is to develop these complex models. It has to be done with the finesse of Emulate Bio, but by taking a HemoShear Theraputics approach to view the platform as the catalyst for the drug pipeline itself on a specific disease. This will lead to many more wins and more valuable drugs coming to market faster, at a cheaper price albeit doing more heavy lifting up front. So while not easy, either make drugs on your own platform or sell the platform in return to be a full partner on the royalties. That’s where the ROI will be for now.